Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : Announces FDA Approval of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder

06/02/2021 | 09:10am EDT

DUBLIN - Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity.

'Schizophrenia and bipolar I disorder are complex, chronic diseases and there remains a persistent need for new medications with proven efficacy and safety. Olanzapine, a highly-efficacious atypical antipsychotic, is associated with significant side effects, including weight gain, that may impact patients' treatment experiences and limit its use,' said Rene S. Kahn, M.D., Ph.D., Esther and Joseph Klingenstein Professor & Chair, Department of Psychiatry and Behavioral Health System at the Icahn School of Medicine at Mount Sinai. 'With the efficacy of olanzapine and evidence of less weight gain in patients with schizophrenia, LYBALVI brings a welcome new addition to our medication arsenal.'

'LYBALVI represents an important new treatment option for adults with schizophrenia or bipolar I disorder, their clinicians and caregivers, and reflects Alkermes' commitment to developing new therapies that support patient-centered care,' said Richard Pops, Chairman and Chief Executive Officer at Alkermes. 'We share this accomplishment with our employees and the many researchers, advocates, clinicians and patients who have been essential to the LYBALVI development program since its inception. Our existing commercial capabilities and presence in the antipsychotic market with ARISTADA provide an important foundation for the commercialization of LYBALVI, and we look forward to making this new medicine available to patients and clinicians later this year.'

In the ENLIGHTEN clinical development program, LYBALVI demonstrated antipsychotic efficacy, safety and tolerability, including statistically significantly less weight gain than olanzapine in patients with schizophrenia in the ENLIGHTEN-2 study. Results from the ENLIGHTEN program's pivotal ENLIGHTEN-1 efficacy study and ENLIGHTEN-2 weight study have been published in peer-reviewed journals1,2 and are included in the approved labeling for LYBALVI. The FDA approved LYBALVI under the 505(b)(2) regulatory pathway based on data from 27 clinical studies, including 18 studies evaluating LYBALVI and nine studies evaluating samidorphan alone, and the FDA's findings of safety and effectiveness of olanzapine in the treatment of bipolar I disorder and schizophrenia. Data suggest that olanzapine-associated weight gain is disease independent.3

'People living with schizophrenia or bipolar I disorder must evaluate both efficacy and tolerability when making treatment decisions,' said Paul Gionfriddo, President and CEO of Mental Health America (MHA). 'We are grateful that companies like Alkermes are driven to continue developing new treatment options in psychiatry that seek to address unmet needs of our community and we applaud the FDA for considering the experiences of individuals living with these conditions.'

Alkermes expects to make LYBALVI available for patients in the fourth quarter of 2021.

Conference Call

Alkermes will host a conference call for analysts and investors on Tuesday, June 1, 2021 at 8:30 a.m. ET (1:30 p.m. BST). The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. To participate in the question and answer session, please dial in to the conference call, which may be accessed by dialing +1 877-407-2988 for U.S. callers and +1 201-389-0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website or by dialing +1 877-660-6853 for U.S. callers and +1 201-612-7415 for international callers, using replay access code 13719944. The conference call replay will be available from 11:30 a.m. ET (4:30 p.m. BST) on Tuesday, June 1, 2021, through Tuesday, June 8, 2021.

About Schizophrenia

Schizophrenia is a serious brain disorder marked by positive symptoms (hallucinations and delusions, disorganized speech and thoughts, and agitated or repeated movements) and negative symptoms (depression, blunted emotions and social withdrawal).4 Schizophrenia affects approximately 1.1% of the U.S. population.5

About Bipolar I Disorder

Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function. Individuals with this brain disorder may experience debilitating changes in mood from extreme highs (mania) to extreme lows (depression). Bipolar I disorder is characterized by the occurrence of at least one manic episode, with or without the occurrence of a major depressive episode, and affects approximately one percent of the adult population in the United States in any given year.6

About the ENLIGHTEN Clinical Development Program

The ENLIGHTEN clinical development program for LYBALVI includes two key studies in patients with schizophrenia: ENLIGHTEN-1 and ENLIGHTEN-2.

ENLIGHTEN-1 evaluated the antipsychotic efficacy, safety and tolerability of LYBALVI compared to placebo over four weeks in 403 patients experiencing an acute exacerbation of schizophrenia. This study met its prespecified primary endpoint, with LYBALVI demonstrating statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) scores compared to placebo (p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ALKERMES PLC
08/02ALKERMES : Secures FDA Fast Track Designation for Melanoma Treatment
08/02ALKERMES : Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Trea..
07/29ALKERMES : Reports Second Quarter 2021 Financial Results
07/29ALKERMES : Mizuho Securities Adjusts Alkermes' Price Target to $33 From $29, Mai..
07/29ALKERMES : SVB Leerink Adjusts Alkermes' Price Target to $25 From $23, Keeps Mar..
07/28ALKERMES : Reports Earnings, Revenue Increase for Q2, Raises Full-Year Guidance
07/28ALKERMES : Management's Discussion and Analysis of Financial Condition and Resul..
07/28ALKERMES : Q2 2021 Earnings slides Final 7 27 21 607pm.pdf
07/28ALKERMES : Q2 Earnings Snapshot
07/28ALKERMES : Reports Second Quarter 2021 Financial Results (Form 8-K)
More news
Financials (USD)
Sales 2021 1 171 M - -
Net income 2021 -79,9 M - -
Net cash 2021 365 M - -
P/E ratio 2021 -56,5x
Yield 2021 -
Capitalization 4 346 M 4 346 M -
EV / Sales 2021 3,40x
EV / Sales 2022 3,05x
Nbr of Employees 2 245
Free-Float 96,7%
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 10
Last Close Price 26,94 $
Average target price 25,00 $
Spread / Average Target -7,20%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC35.04%4 346
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
CELLTRION, INC.-26.60%30 059
SEAGEN INC.-11.93%27 907